BeOne Medicines AG
BEIGF
$22.50
-$1.25-5.25%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.67B | 5.30B | 4.94B | 4.54B | 4.15B |
| Total Other Revenue | 65.11M | 47.75M | 35.81M | 26.69M | 26.69M |
| Total Revenue | 5.74B | 5.34B | 4.97B | 4.56B | 4.18B |
| Cost of Revenue | 670.75M | 668.54M | 686.68M | 660.63M | 634.16M |
| Gross Profit | 5.07B | 4.67B | 4.29B | 3.90B | 3.54B |
| SG&A Expenses | 2.18B | 2.08B | 2.03B | 1.96B | 1.86B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.05B | 4.90B | 4.79B | 4.66B | 4.47B |
| Operating Income | 685.94M | 447.14M | 182.68M | -100.70M | -295.75M |
| Income Before Tax | 655.17M | 416.85M | 182.26M | -63.21M | -268.68M |
| Income Tax Expenses | 142.15M | 129.92M | 113.71M | 114.44M | 123.69M |
| Earnings from Continuing Operations | 513.02 | 286.93 | 68.55 | -177.64 | -392.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 513.02M | 286.93M | 68.55M | -177.64M | -392.37M |
| EBIT | 685.94M | 447.14M | 182.68M | -100.70M | -295.75M |
| EBITDA | 825.39M | 578.82M | 328.98M | 79.96M | -121.20M |
| EPS Basic | 60.49 | 34.01 | 7.62 | -22.00 | -48.27 |
| Normalized Basic EPS | 4.04 | 2.71 | 1.18 | -0.32 | -1.54 |
| EPS Diluted | 55.81 | 30.61 | 5.06 | -23.67 | -49.02 |
| Normalized Diluted EPS | 3.88 | 2.61 | 1.11 | -0.35 | -1.55 |
| Average Basic Shares Outstanding | 440.22M | 436.19M | 431.72M | 427.41M | 423.79M |
| Average Diluted Shares Outstanding | 35.25M | 34.89M | 34.19M | 33.53M | 32.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -8.16% | -3.69% |